Article
Pharmacology & Pharmacy
Marina de Souza Guimaraes, Jorge Javier Muso Cachumba, Cecilia Zorzi Bueno, Karin Mariana Torres-Obreque, Grace Veronica Ruiz Lara, Gisele Monteiro, Leandro Ramos Souza Barbosa, Adalberto Pessoa Jr, Carlota de Oliveira Rangel-Yagui
Summary: L-asparaginase is an important biological drug used for the treatment of Acute Lymphoblastic Leukemia. Encapsulation of L-asparaginase in liposomes provides protection against degradation and improves the pharmacokinetics of the drug. The study showed that the encapsulated L-asparaginase exhibited enhanced activity and improved protection against immune recognition and protease degradation in vitro and in vivo.
Article
Oncology
Meghan McCormick, Jillian Lapinski, Erika Friehling, Kenneth Smith
Summary: Compared with other strategies, the use of premedication and therapeutic drug monitoring in children with B-ALL is potentially cost-saving. Premedication in combination with monitoring resulted in fewer changes to Erwinia doses and the most quality-adjusted life years gained in standard-risk patients. Sensitivity analyses showed that premedication and monitoring remained favorable in the majority of iterations.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Education, Scientific Disciplines
Nicolas Boissel
Summary: The outcome for AYA with ALL has improved, but further advancements are expected from the expanding knowledge of ALL biology and the early introduction of targeted therapies. The identification of specific targets remains challenging, and MRD monitoring has become a standard for risk stratification. Immunotherapies are being approved to eradicate MRD and improve outcomes for high-risk patients. Comprehensive care programs are crucial for improving inclusion in clinical trials and providing psychosocial support for AYA cancer patients.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
(2022)
Article
Oncology
Amin Azem, Ryan Caddell, Rebecca Nelson, Leidy Isenalumhe, Sameh Gaballa, Julio Chavez, Celeste Bello, Javier Pinilla, Lubomir Sokol, Bijal Shah, Hayder Saeed
Summary: This study investigated the toxicity of replacing L-asparaginase with PEG-asparaginase in the mSMILE regimen. The results showed that, in a non-Asian population, the mSMILE regimen with PEG-asparaginase is a safe alternative to the L-asparaginase-based SMILE regimen. The risk of hematological toxicity is comparable, and no treatment-related mortality was observed.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Montserrat Mesegue, Anna Alonso-Saladrigues, Sara Perez-Jaume, Ariadna Comes-Escoda, Jose Luis Dapena, Anna Faura, Nuria Conde, Albert Catala, Anna Ruiz-Llobet, Edgar Zapico-Muniz, Mireia Camos, Susana Rives
Summary: The study compared allergic reactions in children receiving native E. coli-ASP and PEG-ASP within the same clinical protocol. It showed that patients upfront administered with PEG-ASP had a lower allergy incidence and most achieved adequate ASP activity levels.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Medical Laboratory Technology
Omid R. Zekavat, Afsoon Safari, Mohammad R. Bordbar, Sezaneh Haghpanah, Soheila Zareifar, Mahdi Shahriari, Malihe Mohammadzadeh
Summary: This study compared the effects of PEG-ASP and L-ASP on coagulation markers in pediatric patients with ALL, finding that L-ASP had a more prominent negative effect on anticoagulant factors, while the risk of thrombosis was likely lower with PEG-ASP.
CLINICAL LABORATORY
(2022)
Article
Oncology
Alexander Popov, Gunter Henze, Julia Roumiantseva, Oleh Bydanov, Mikhail Belevtsev, Tatiana Verzhbitskaya, Liudmila Movchan, Grigory Tsaur, Svetlana Lagoyko, Liudmila Zharikova, Natalia Myakova, Dmitry Litvinov, Olga Khlebnikova, Olga Streneva, Elena Stolyarova, Natalia Ponomareva, Galina Novichkova, Larisa Fechina, Olga Aleinikova, Alexander Karachunskiy
Summary: This report presents the results of using PEG-ASP in the treatment of childhood B-cell precursor acute lymphoblastic leukemia. The randomized use of PEG-ASP at a dose of 1000 U/m2 on day 3 of induction therapy resulted in a significantly larger proportion of rapidly responding patients. These rapid responders showed excellent long-term outcomes even with low-intensity therapy.
Article
Hematology
Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrozek, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Frederick R. Appelbaum, Harry P. Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson, Anjali S. Advani, Wendy Stock, Selina M. Luger
Summary: Asparaginase is an important part of pediatric-inspired regimens for young adults with ALL. Truncation of asparaginase therapy is associated with worse outcomes in children with ALL, but the correlation in adults is lacking. This study investigated the prevalence and risk factors of PEG-asparaginase discontinuation in young adults with ALL, and found that early discontinuation may adversely impact survival in patients with standard-risk ALL.
Article
Oncology
Rachael Schulte, Ashley Hinson, Van Huynh, Erin H. Breese, Joanna Pierro, Seth Rotz, Benjamin A. Mixon, Jennifer L. McNeer, Michael J. Burke, Etan Orgel
Summary: The study shows that obese and adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) are at higher risk of PEG-ASP-associated hepatotoxicity, and that levocarnitine supplementation may have a protective effect.
Article
Environmental Sciences
Sulaiman A. Al Yousef
Summary: Asparaginase plays a crucial role in leukemia treatment as part of chemotherapy. It is isolated from Fusarium sp. and characterized as a metalloprotease with specific inhibitory and activating effects on different ions and substrates. The enzyme also exhibits antileukemic activity with a potential as a chemotherapeutic agent.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2022)
Article
Hematology
Carmelo Rizzari, Anja Moericke, Maria Grazia Valsecchi, Valentino Conter, Martin Zimmermann, Daniela Silvestri, Andishe Attarbaschi, Felix Niggli, Draga Barbaric, Jan Stary, Sarah Elitzur, Gunnar Cario, Luciana Vinti, Joachim Boos, Massimo Zucchetti, Claudia Lanvers-Kaminsky, Arend von Stackelberg, Andrea Biondi, Martin Schrappe
Summary: This study evaluated the incidence of hypersensitivity reactions (HSRs) to PEG-ASNase in children with ALL. The results showed that the intensification of PEG-ASNase did not significantly affect the HSR incidence in BCP-MR patients, but significantly impacted HR patients. Among non-HR groups, the use of PEG-ASNase did not increase the risk of HSR, while the HSR incidence was significantly higher in HR-SA patients compared to HR-EA patients.
Article
Gastroenterology & Hepatology
Shu-Han Kuo, Jiann-Shiuh Chen, Chao-Neng Cheng, Hsiao-Yu Lo, Wei-Che Chen, Fu-Ping Lai, Yao-Jong Yang
Summary: This study aimed to investigate the characteristics and risk factors for asparaginase-associated pancreatitis (AAP) in pediatric acute lymphoblastic leukemia (ALL) patients under the Taiwan Pediatric Oncology Group (TPOG)-ALL regimen. The incidence of AAP was 4.7% in patients treated with the TPOG-ALL protocol, and the use of the TPOG-ALL-2013 protocol was identified as an independent risk factor. Pancreatic necrosis, pseudocysts, diabetes mellitus, and chronic pancreatitis were observed in some patients during the observational period.
Article
Obstetrics & Gynecology
C. Decanter, J. Delepine, H. Behal, S. Manier, B. Bruno, M. Barbatti, C. Robin, J. Labreuche, F. Morschhauser, P. Pigny
Summary: Age and chemotherapy regimen can affect ovarian function in lymphoma patients, with alkylating regimens causing follicular depletion and non-alkylating regimens showing low ovarian toxicity. Early age does not necessarily protect against ovarian damage from chemotherapy.
HUMAN REPRODUCTION
(2021)
Article
Oncology
Todd William Mudd, Ashley Danielle Fox, Mark Ghaly, Amany Keruakous
Summary: PEG-asparaginase induces antitumor effect by depleting asparagine, but can cause pancreatitis and hypertriglyceridemia. This report presents a case of a 22-year-old woman with T-ALL who developed pancreatitis, hypertriglyceridemia, and hyperosmolar hyperglycemic syndrome after receiving PEG-asparaginase treatment. Providers should be aware of the association between PEG-asparaginase and these metabolic complications.
FRONTIERS IN ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Lauren Repp, Morteza Rasoulianboroujeni, Hye Jin Lee, Glen S. Kwon
Summary: The use of PEG-b-PLA and PEG-b-PCL nano-assemblies can enhance the water solubility of anticancer drugs, have lower toxicity compared to traditional organic solvents or solubilizers, and the prodrugs combined in the nano-assemblies significantly enhance the anticancer efficacy.
JOURNAL OF CONTROLLED RELEASE
(2021)